Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6
30 Octobre 2017 - 1:00PM
Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that
it will host a webcast and conference call to discuss the company’s
financial results for the quarter ended September 30, 2017, and
provide a general business overview on Monday, November 6, 2017, at
4:30 p.m. ET (1:30 p.m. PT).
Conference Call DetailsThe live conference call
on Monday, November 6, 2017, at 4:30 p.m. Eastern Time, can be
accessed by phone by calling (844) 452-6828 from the United States
and Canada or (765) 507-2588 internationally and using the passcode
7269839. The webcast can be accessed live on the Investor Relations
section of the Company's website at http://investors.portola.com.
It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc. Portola
Pharmaceuticals is a biopharmaceutical company developing product
candidates that could significantly advance the fields of
thrombosis and other hematologic diseases. The Company’s first
medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa
inhibitor, was approved by the U.S. Food and Drug Administration in
June 2017. The company is also working to advance two clinical
programs for AndexXa® (andexanet alfa), a recombinant protein
designed to reverse the anticoagulant effect in patients treated
with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a
SYK/JAK inhibitor in development to treat hematologic cancers.
Portola's partnered program is focused on developing selective SYK
inhibitors for inflammatory conditions. For more information, visit
http://www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Investor Contact:Michele MantynenPortola
PharmaceuticalsIR@portola.com
Media Contact:Patrick RyanW2O
Grouppryan@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur